Skip to main content

Janssen Research Foundation

, a unit of

Johnson & Johnson


, received approval from the

Food and Drug Administration

to market Reminyl, a drug for treating Alzheimer's disease.

Reminyl, which is derived from daffodil bulbs, can either delay or stabilize Alzheimer's symptoms. Janssen developed the drug under a co-development and licensing agreement with

Shire Pharmaceuticals

Scroll to Continue

TheStreet Recommends



The drug has already been approved in 21 other countries, including most major European markets. Janssen and

Ortho-McNeil Pharmaceutical

will jointly market Reminyl in the U.S.

During regular trading on the

New York Stock Exchange

, Johnson & Johnson, a component of the

Dow Jones Industrial Average

, gained $1.38, or 1.4%, to close at $97.33.